ARA-290 vs NNZ-2591
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Cibinetide, ARA 290
ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide carved from the tissue-protective region of erythropoietin (EPO), engineered to calm inflammation and repair nerves without thickening the blood the way EPO does. It has been tested in real Phase 2 human trials, mainly for sarcoidosis-related small fiber neuropathy and diabetic neuropathy, and holds FDA orphan drug status, but it was never approved and development largely stalled. So: genuine clinical data, promising signals, no finish line.
Also: Cyclo-L-glycyl-L-2-allylproline, Cyclic glycine-proline analog
NNZ-2591 is Neuren Pharmaceuticals' second drug, a synthetic analog of cyclic glycine-proline (cGP), a small ring-shaped molecule the body makes when it breaks down IGF-1. It is taken by mouth and is being developed for rare childhood neurodevelopmental disorders: Phelan-McDermid syndrome is furthest along, with the first-ever phase 3 trial in that disease started in late 2025, and Angelman and Pitt Hopkins syndromes behind it. Phase 2 results looked encouraging, but they were small open-label studies, so nobody knows yet whether it truly works.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
Detailed Comparison
| Attribute | ARA-290 | NNZ-2591 |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | EPO does two jobs - it tells bone marrow to make red blood cells, and separately it protects and repairs injured tissue. ARA-290 was designed to trigger only the second job. It selectively activates the innate repair receptor (IRR), a heteroreceptor that pairs the EPO receptor with the CD131 beta-common chain and shows up at sites of injury and inflammation. By switching on this receptor, the peptide dampens inflammatory signaling and reduces cell death while leaving red blood cell production alone, which sidesteps EPO's clotting and cardiovascular risks. Some research also links its pain-relieving effect to modulation of the TRPV1 channel where the immune system and nociception intersect. | Cyclic glycine-proline is thought to fine-tune IGF-1 activity in the brain by changing how IGF-1 binds to its carrier protein IGFBP-3. A 2014 Scientific Reports study proposed that cGP nudges IGF-1 activity up when it is low and down when it is high, a normalizing effect rather than a simple boost. NNZ-2591 adds an allyl group to the proline ring, making it resistant to enzymes and able to reach the brain after oral dosing. Trial protocols also describe reduced neuroinflammation and support for synapse function in animal models. It is a close cousin of trofinetide in spirit (both are small IGF-1-derived molecules from the same company), but the exact way it helps in these genetic syndromes has not been pinned down in humans. |
| Common Dosing | 4 mg daily Once daily | 12 mg/kg twice daily (phase 2 target trial dose) Twice daily |
| Administration | Subcutaneous injection | Oral liquid |
| Typical Duration | 28-day courses in trials | 13 weeks in phase 2 and phase 3 trials, with 12-month open-label extensions |
| Best Time to Take | Consistent daily timing | Twice daily (trial schedule) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | ARA-290 has more real human data than most peptides in this category. A 2015 phase 2 trial published in Molecular Medicine (Brines et al., registered as NTR3858) found that ARA-290 improved hemoglobin A1c and lipid profile and significantly improved PainDetect neuropathic symptom scores in type 2 diabetes patients, with increased corneal nerve fiber density in those with small fiber neuropathy. In sarcoidosis-associated small fiber neuropathy, controlled studies reported increased corneal nerve fiber area and more regenerating (GAP-43-positive) skin nerve fibers, though in at least one dose-ranging trial pain did not clearly separate from placebo - an honest caveat worth keeping. Tolerability in these small, early-phase studies has been favorable, with no signal of EPO-style blood thickening. That said, the trials are small and early, ARA-290 holds FDA orphan drug status for sarcoidosis neuropathy but is not approved, and the program stalled around 2020. Net: real clinical evidence pointing in a hopeful direction, but not yet proven enough to be a standard treatment. | The human data so far come from three small, open-label phase 2 trials of 13 weeks each, all with twice-daily oral dosing titrated up to a target of 12 mg/kg. In Phelan-McDermid syndrome (18 children, published in Neurology Genetics in 2026), 10 of 14 efficacy measures improved significantly from baseline, including clinician and caregiver global ratings, behavior, sleep and communication, and the drug was well tolerated with mostly mild to moderate side effects. Angelman syndrome (reported August 2024) showed a mean CGI-I of 3.0, with 11 of 13 children rated improved by clinicians. Pitt Hopkins syndrome (reported May 2024) showed improvement in 6 of 11 children on clinician-rated severity. The big caveat: none of these had a placebo group, and rare-disease trials with caregiver-rated outcomes are especially prone to placebo effects. A planned Prader-Willi trial was withdrawn before enrolling anyone. The real test is Koala, a randomized, double-blind, placebo-controlled phase 3 trial in about 160 children aged 3 to 12 with Phelan-McDermid syndrome (first patient dosed February 2026; estimated primary completion late 2027), with an open-label extension started in 2026. The FDA has given the program Fast Track, Rare Pediatric Disease and Orphan Drug designations. Neuren has also started work in neonatal hypoxic-ischemic encephalopathy, which is still preclinical. |
Frequently Asked Questions: ARA-290 vs NNZ-2591
What is the difference between ARA-290 and NNZ-2591?
ARA-290 is a cognitive peptide that ara-290 (cibinetide) is a synthetic 11-amino-acid peptide carved from the tissue-protective region of erythropoietin (epo), engineered to calm inflammation and repair nerves without thickening the blood the way epo does. it has been tested in real phase 2 human trials, mainly for sarcoidosis-related small fiber neuropathy and diabetic neuropathy, and holds fda orphan drug status, but it was never approved and development largely stalled. so: genuine clinical data, promising signals, no finish line. NNZ-2591 is a cognitive peptide that nnz-2591 is neuren pharmaceuticals' second drug, a synthetic analog of cyclic glycine-proline (cgp), a small ring-shaped molecule the body makes when it breaks down igf-1. it is taken by mouth and is being developed for rare childhood neurodevelopmental disorders: phelan-mcdermid syndrome is furthest along, with the first-ever phase 3 trial in that disease started in late 2025, and angelman and pitt hopkins syndromes behind it. phase 2 results looked encouraging, but they were small open-label studies, so nobody knows yet whether it truly works. The main differences lie in their mechanisms of action and clinical applications.
Which is better, ARA-290 or NNZ-2591?
Neither is universally "better" - the choice depends on your specific goals. ARA-290 is typically used for cognitive purposes, while NNZ-2591 is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can ARA-290 and NNZ-2591 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using ARA-290 and NNZ-2591 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.